Cover Image
市場調查報告書

RNAi 治療市場:2015-2030年

RNAi Therapeutics Market, 2015 - 2030

出版商 ROOTS ANALYSIS 商品編碼 345882
出版日期 內容資訊 英文 387 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
RNAi 治療市場:2015-2030年 RNAi Therapeutics Market, 2015 - 2030
出版日期: 2015年12月01日 內容資訊: 英文 387 Pages
簡介

本報告提供RNAi治療擴大的開發平台目前市場情況及未來展望、開發中產品 (臨床/前臨床的雙方) 的開發階段與對象的適應症、RNAi的領域中的新技術平台與輸送技術、聯盟趨勢、投資趨勢、競爭情形及今後的預測彙整,為您概述為以下內容。

第1章 序論

第2章 摘要整理

第3章 簡介

  • 背景、內容
  • RNAi的發現
  • RNAi的機制
  • RNAi分子的種類與其作用機制
  • RNAi的應用
  • RNAi治療的產業階段
  • RNAi的優點及缺點
  • 法規指南

第4章 市場概要

  • 本章概要
  • 流通:各開發階段
  • 臨床實驗平台
    • 各分子類型
    • 各治療領域
    • 各給藥途徑
  • 前臨床開發平台

第5章 技術平台、輸送系統

  • 本章概要
  • siRNA的輸送:輸送系統的零組件
    • siRNA觸發器
    • siRNA輸送技術
  • siRNA奈米粒子輸送的專利形勢

第6章 地區市場

  • 本章概要
  • 美國
    • Alnylam Pharmaceuticals
    • Arrowhead Research
    • DiGradalis cerna Pharmaceuticals
    • miRagen Therapeutics
    • Mirna Therapeutics
    • Quark Pharmaceuticals
    • RXi Pharmaceuticals
    • Sirnaomics
  • 歐洲
    • Silence Therapeutics
    • Sylentis
  • 其他 (RoW)
    • Arbutus Biopharma (previously Tekmira)
    • Benitec Biopharma
    • Silenseed

第7章 市場預測

  • 本章概要
  • 調查範圍、限制
  • 預測手法
  • RNAi治療市場整體
  • 各治療預測

第8章 主要治療指標

  • 本章概要
  • 感染疾病
  • 癌症
  • 眼科
  • 心臟疾病

第9章 RNAi及診斷

  • 本章概要
  • 生物標記的特徵
  • 生物標記的miRNA的循環
  • miRNA生物標記和癌症
    • 癌症的早期發現的重要性
    • 癌症的檢測:檢驗 vs. 診斷
    • 傳統的侵入性癌症診斷檢驗
    • 微創方法的必要性
    • 主要的癌症適應症
  • miRNA的生物標記和心血管疾病
    • 心肌梗塞 (MI)
    • 冠狀動脈疾病 (CAD)
  • miRNA型診斷檢驗的開發平台

第10章 RNAi治療的創業投資 (VC) 資金

  • 本章概要
  • RNAi治療的資金的案例
  • 創業投資利息的增加
  • 資金分配的案例:資金各類型
  • 按主要企業:資金案例的分配

第11章 市場預測

  • 本章概要
  • 聯盟模式/協定
  • 產業合作、合作
  • 跟研究機關/大學的合作

第12章 RNAi治療的服務供應商

  • 本章概要
  • 服務供應商

第13章 SWOT分析

  • 概要
  • 優勢
  • 弱點
  • 機會
  • 威脅

第14章 結論

  • RNAi治療:藥物研發以困難的東西為目標
  • 積極合作為詳細成功的關鍵
  • RNAi治療:新興市場
  • RNAi治療的輸送:主要的障礙
  • 帶來數十億美元規模市場的強力開發平台

第15章 附錄1:表格形式資料

第16章 附錄2:企業、組織的清單

圖表

目錄
Product Code: RA10051

Discovered less than two decades ago, RNAi has made its presence felt in all spheres of the pharmaceutical industry. RNAi is a natural post-transcriptional process of gene silencing involving short strands of nucleic acids. It is a regulatory process that cells utilise to silence and/or inhibit gene expression through the destruction of specific mRNA molecules. One of the major advantages of RNAi is that it enables sequence specific knockdown of a target gene. Indications, such as age-related macular degeneration (AMD), hepatitis C and various forms of cancer,which are hard to address with the available therapies, are being considered as potential areas that can benefit from RNAi based therapeutics.

After years of research tracing back to the 1990s, a number of novel RNAi therapeutics have finally reached a point of maturity. These promising therapeutic approaches are set to be made commercially available in the near future. Innovative research, encouraging clinical trial results and growing pipelines directed towards a variety of molecular targets across different therapeutic areas have emerged as essential growth drivers of the market. The promise has been backed by several venture capitalists and strategic investors. It is also important to highlight that partnerships amongst various stakeholders in this market have been common. Such collaborations have actively fuelled growth in the market by providing a common platform for both industry and academic research.

Several start-ups / university spin-offs have been notable flagbearers and are expected to sustain the research momentum in the coming years. The commercial success, to a certain extent, is hinged upon uncovering effective delivery routes and developing sophisticated delivery carriers for the molecules. Despite this and other associated challenges, we expect the market to make a huge leap over the coming decade.

The ‘RNAi Therapeutics Market, 2015-2030' report provides a comprehensive analysis of the current market landscape and future outlook of the growing pipeline of RNAi therapeutics. Overall, the RNAi therapeutics market has been one of the more actively evolving markets in the past few years. However, with no marketed products till date, the market is still in its infancy.

RNAi therapeutics is characterised by a robust and opportunistic pipeline of products targeting several therapeutic areas such as oncology, genetic disorders and infectious diseases. The market has seen several collaborations between industry players aimed at the clinical and commercial development of promising candidates. Some late stage products that have emerged out of such collaborations include Patisiran/ALN-TTR02 (Alnylam Pharmaceuticals and Genzyme; based on LNP delivery platform developed by Arbutus Biopharma), Revusiran/ALN-TTRsc (Alnylam Pharmaceuticals and Genzyme; based on Alnylam's proprietary GalNAc siRNA conjugate platform), QPI-1002 (Quark Pharmaceuticals and Novartis; based on AtuRNAi platform developed by Silence Therapeutics) and PF-655 (Quark Pharmaceuticals and Pfizer; based on AtuRNAi platform developed by Silence Therapeutics). Encouraging clinical results have accelerated the progress and these therapies have emerged as one of the most effective ways of developing treatments for undruggable targets.

Synopsis

One of the key objectives of this study is to review and quantify the opportunities laid by the innovative programs of both small and big pharma firms. The unexploited and promising nature of this market supports the hopes pinned on multiple start-ups by several strategic investors and venture capital firms. We have presented our opinions in this report by analysing:

  • The current state of the market with respect to key players, developmental stage of pipeline products (both clinical/preclinical) and target indications
  • The well established and emerging technology platforms and delivery systems in the space of RNAi (nanoparticle based systems, lipid based systems and conjugated systems)
  • Partnerships that have taken place in the recent past covering research and development collaborations, manufacturing agreements, license agreements specific to technology platforms, co-development and co-commercialisation of promising candidates
  • Various investments and grants received by companies focused in this area
  • Various service providers that are aiding the development of this area as well as providing raw materials for research
  • Competitive landscape and inherent threats to the market's growth in the short and long term
  • Development and sales potential based on target consumer segments, likely adoption rate and expected pricing

The study provides an estimate of the short-midterm and long term market forecast for the period 2015 - 2030. The research, analysis and insights presented in this report include potential sales of several molecules in late (phase III, II/III) and intermediate (phase II) phases of development.

With most products still in the early stage of development, we have provided three market forecast scenarios to add robustness to our model. The conservative, base and optimistic scenarios represent three different tracks of industry evolution. All actual figures have been sourced and analysed from publicly available information. The figures mentioned in this report are in USD, unless otherwise specified.

Example Highlights

  • 1. RNAi therapeutics have emerged as a new class of potent therapies capable of targeting diseases with undruggable targets. A number of disorders that are difficult to treat using traditional approaches can be addressed using this technology.
  • 2. During the course of our research, we identified 180 products in various phases of development. Of these, 20% are in the clinical phase of development (with five molecules in Phase III trials). A significant proportion of the molecules (80%), currently in the preclinical/discovery stages,are likely to fuel the future growth.
  • 3. The market is predominantly being led by emerging start-ups and small companies instead of big pharma companies. Alnylam Pharmaceuticals, Arbutus Biopharma (previously Tekmira), Benitec Biopharma and Quark Pharmaceuticals are some major players in this space. Other start-ups and university / industry spin offs that have come up in recent times include (in alphabetical order) Arrowhead Research, Dicerna Pharmaceuticals, Gradalis, miRagen Therapeutics, Mirna Therapeutics, RXi Pharmaceuticals, Silence Therapeutics, Silenseed, Sirnaomics and Sylentis(full list available in Chapter 4).
  • 4. A large number of players have already collaborated for licensing technology and therapeutic candidates. We have identified and reviewed over 80 such partnerships that have taken place in the last few years. One of the major reasons behind the extensive number of collaborations is that the original trigger and other related mechanisms are well protected through a number of patents.
  • 5. In addition, enhanced technological platforms and unexplored opportunities have yielded an intense framework of investment activity, with a sizeable number of venture capitalists actively supporting the research. Since 2013, we have traced a total investment (equity + debt) of USD 2.2 billion.
  • 6. Over the coming decade, we expect at least 11 RNAi therapies to be made commercially available. We believe the market is likely to be worth USD 18.6 billion by 2030; the overall opportunity could be much higher and depends on a number of factors such as favourable market environment, regulatory regimes and therapeutic performance of candidates in late stages of development.

Research Methodology

Most of the data presented in this report has been gathered via secondary research. For all our projects, we also conduct interviews with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and technology segments. Where possible, the available data has been checked for accuracy from multiple sources of information.

The secondary sources of information include

  • Annual reports
  • Investor presentations
  • SEC filings
  • Industry databases
  • News releases from company websites
  • Government policy documents
  • Industry analysts' views

While the focus has been on forecasting the market over the coming ten years, the report also provides our independent view on various technological and non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various sources of information.

Chapter Outlines

Chapter 2 presents an executive summary of the report. It offers a high level view on where the RNAi therapeutics market is headed in the mid-long term.

Chapter 3 provides a detailed introduction to RNAi therapeutics. In this section, we have discussed the discovery and evolution of RNAi and its mechanism of action. We have also highlighted the advantages and associated challenges, applications areas and the views of the regulatory authorities.

Chapter 4 includes information on over 180 molecules that are currently in different stages of development (both clinical and preclinical/discovery). In this section, we have presented a detailed analysis of the RNAi development pipeline including information on the various types of molecules, most commonly targeted indications, current phases of development and the target gene.

Chapter 5 provides a comprehensive view on the technology platforms and delivery systems that are currently being used in the RNAi therapeutics domain. In addition, the chapter provides an overview on patents protecting the RNAi technology and associated delivery systems, with a specific focus on siRNA.

Chapter 6 provides detailed company and drug profiles of the leading players in the market. Each profile includes information such as the company's financial performance, geographical presence, RNAi pipeline and recent collaborations. Within each profile, we have included detailed clinical trial information for the molecules in the clinical development phase.

Chapter 7 highlights the monetary opportunity presented by these therapies. It provides a comprehensive market forecast analysis for molecules in advanced stages of development (phase III and phase II) taking into consideration the target patient population, competition, likely adoption rate and price points.

Chapter 8 highlights the promising therapeutic areas for RNAi therapeutics. These indications are the prime focus of companies developing RNAi therapeutics. The chapter also highlights the epidemiological facts and currently available treatment options for each indication.

Chapter 9 discusses the use of miRNAs as potential biomarkers and enlists several miRNA biomarkers currently under investigation. In addition, the chapter provides the pipeline of diagnostic kits that have already been approved or are under development.

Chapter 10 presents details on various investments and grants received by companies focused in the area of RNAi therapeutics. The analysis highlights the growing interest from the VC community and other strategic investors in this market.

Chapter 11 features an elaborate discussion on the collaborations and partnerships that have been forged amongst the players in the market.We have also discussed the various partnership models in existence and the most common forms of deals/agreements that have evolved over time.

Chapter 12 provides information on the companies that are actively supporting the development of RNAi therapeutics market. These include companies such as contract manufacturers, contract researchers and other service providers.

Chapter 13 provides a SWOT analysis of the RNAi therapeutics market, giving strategic insights to the major factors that are likely to drive future growth whilst also highlighting the weaknesses and threats that may negatively impact the industry's evolution.

Chapter 14 summarises the overall report. In this chapter, we provide a recap of the key takeaways and our independent opinion based on the research and analysis described in previous chapters.

Chapters 15 and 16 are appendices, which provide the list of companies and tabulated data for all the figures presented in the report.

Table of Contents

1. PREFACE

  • 1.1. Scope of the Report
  • 1.2. Research Methodology
  • 1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

  • 3.1. Background and Context
  • 3.2. Discovery of RNAi
  • 3.3. Mechanism of RNAi
    • 3.3.1. Components of RNAi
    • 3.3.2. Cellular Mechanism
  • 3.4. Types of RNAi Molecules and Their Mode of Action
    • 3.4.1. siRNA
      • 3.4.1.1. Mechanism of Action
    • 3.4.2. miRNA
      • 3.4.2.1. Mechanism of Action
    • 3.4.3. shRNA
      • 3.4.3.1. Mechanism of Action
  • 3.5. Applications of RNAi
    • 3.5.1. Functional Genomics
    • 3.5.2. Therapeutics
    • 3.5.3. Biotechnology
    • 3.5.4. Genome-Scale Screening
  • 3.6. Industrial Phases of RNAi Therapeutics
  • 3.7. Advantages and Disadvantages of RNAi
  • 3.8. Regulatory Guidelines

4. MARKET OVERVIEW

  • 4.1. Chapter Overview
  • 4.2. Distribution by Phase of Development
  • 4.3. Clinical Pipeline
    • 4.3.1. RNAi Clinical Pipeline: Distribution by Type of Molecule
    • 4.3.2. RNAi Clinical Pipeline: Distribution by Therapeutic Area
    • 4.3.3. RNAi Clinical Pipeline: Distribution by Route of Administration
    • 4.3.4. Active Industry Players in the Clinical Development
  • 4.4. Preclinical Pipeline
    • 4.4.1. RNAi Preclinical Pipeline: Distribution by Therapeutic Area
    • 4.4.2. RNAi Preclinical Therapeutics: Distribution by Type of Molecule
    • 4.4.3. Active Industry Players in Preclinical Development

5. TECHNOLOGY PLATFORMS AND DELIVERY SYSTEMS

  • 5.1. Chapter Overview
  • 5.2. Delivering siRNAs: Components of a Delivery System
    • 5.2.1. siRNA Trigger
      • 5.2.1.1. Proprietary siRNA (AtuRNAi)
      • 5.2.1.2. Dicer Substrate siRNA (DsiRNA)
      • 5.2.1.3. Self-Delivering RNAi (sd-rxRNA)
      • 5.2.1.4. siRNA Based on Tuschl II Patent Family
      • 5.2.1.5. Unlocked Nucleobase Analog (UNA)-containing siRNA (UsiRNA)
    • 5.2.2. siRNA Delivery Technologies
      • 5.2.2.1. Available Technology Platforms and Delivery Systems in the Market
      • 5.2.2.2. Formulating Cationic Liposomes: The Most Common Lipid Based Nanoparticle Systems for RNA Delivery
      • 5.2.2.3. Lipid Based Nanoparticles
        • 5.2.2.1.1. Lipoplex Delivery Technology, Silence Therapeutics
          • 5.2.2.1.1.1. Technology Overview
          • 5.2.2.1.1.2. Delivery Systems and Pipeline Molecules in Development
          • 5.2.2.1.1.3. Patent Portfolio
        • 5.2.2.1.2. Stable Nucleic Acid-Lipid Particles (SNALP), Arbutus Biopharma (Formerly Tekmira)
          • 5.2.2.1.2.1. Technology Overview
          • 5.2.2.1.2.2. Pipeline Molecules in Development
          • 5.2.2.1.2.3. Patent Portfolio
        • 5.2.2.1.3. EnCore Lipid Nanoparticles, Dicerna Pharmaceuticals
          • 5.2.2.1.3.1. Technology Overview
          • 5.2.3.1.3.2. Pipeline Molecules in Development
          • 5.2.2.1.3.3. Patent Portfolio
      • 5.2.2.2. Polymer Based Nanoparticles
        • 5.2.2.2.1. RONDEL, Arrowhead Research
          • 5.2.2.2.1.1. Technology Overview
          • 5.2.2.2.1.2. Pipeline Molecules in Development
      • 5.2.2.3. Conjugated Delivery Systems
        • 5.2.2.3.1. Dynamic Polyconjugates (DPC), Arrowhead Research
          • 5.2.2.3.1.1. Technology Overview
          • 5.2.2.3.1.2. Pipeline Molecules in Development
          • 5.2.2.3.1.3. Patent Portfolio
        • 5.2.2.3.2. GalNAc Conjugate Delivery System, Alnylam Pharmaceuticals
          • 5.2.2.3.2.1. Technology Overview
          • 5.2.2.3.2.2. Pipeline Molecules in Development Based on the Technology Platform
          • 5.2.2.3.2.3. Patent Portfolio
  • 5.3. Patent Landscape of siRNA Nanoparticle Delivery
    • 5.3.1. Frequent Filers at the USPTO
    • 5.3.2. Fundamental Patents for siRNA

6. REGIONAL MARKET

  • 6.1. Chapter Overview
  • 6.2. US
    • 6.2.1. Alnylam Pharmaceuticals
    • 6.2.1.1. Company Overview
    • 6.2.1.2. Financial Performance
    • 6.2.1.3. Technology Snapshot
    • 6.2.1.4. Drug Portfolio
      • 6.2.1.4.1. Clinical Development
      • 6.2.1.4.2. Preclinical Development
    • 6.2.1.5. Patents
    • 6.2.1.6. Collaborations
      • 6.2.1.6.1. Isis Pharmaceuticals
      • 6.2.1.6.2. Alpha-1 Foundation
      • 6.2.1.6.3. Genzyme
      • 6.2.1.6.4. Merck (Acquisition of Sirna Therapeutics)
      • 6.2.1.6.5. The Medicines Company
      • 6.2.1.6.6. Arbutus Biopharma (previously Tekmira)
      • 6.2.1.6.7. Monsanto
      • 6.2.1.6.8. Ascletis Pharmaceuticals
      • 6.2.1.6.9. Arrowhead Research
      • 6.2.1.6.10. Sylentis
      • 6.2.1.6.11. Cubist
      • 6.2.1.6.12. Calando Pharmaceuticals
      • 6.2.1.6.13. Kyowa Hakko
      • 6.2.1.6.14. Takeda Pharmaceuticals
      • 6.2.1.6.15. Roche
      • 6.2.1.6.16. Regulus Therapeutics
      • 6.2.1.6.17. Quark Pharmaceuticals
      • 6.2.1.6.18. GeneCare Research Institute
      • 6.2.1.6.19. Novartis
      • 6.2.1.6.20. Benitec Biopharma
      • 6.2.1.6.21. Medtronic
    • 6.2.2. Arrowhead Research
      • 6.2.2.1. Company Overview
      • 6.2.2.2. Financial Performance
      • 6.2.2.3. Technology Snapshot
      • 6.2.2.4. Drug Portfolio
        • 6.2.2.4.1. Clinical Development
        • 6.2.2.4.2. Preclinical Development
      • 6.2.2.5. Patents
      • 6.2.2.6. Collaborations
        • 6.2.2.6.1. Novartis
        • 6.2.2.6.2. Alnylam Pharmaceuticals
        • 6.2.2.6.3. Roche
    • 6.2.3. Dicerna Pharmaceuticals
      • 6.2.3.1. Company Overview
      • 6.2.3.2. Financial Performance
      • 6.2.3.3. Technology Snapshot
      • 6.2.3.4. Drug Portfolio
        • 6.2.3.4.1. Clinical Development
        • 6.2.3.4.2. Preclinical Development
      • 6.2.3.5. Patents
      • 6.2.3.6. Collaborations
        • 6.2.3.6.1. Arbutus Biopharma (previously Tekmira)
        • 6.2.3.6.2. Ipsen
        • 6.2.3.6.3. Kyowa Hakko Kirin
        • 6.2.3.6.4. Archemix
    • 6.2.4. Gradalis
      • 6.2.4.1. Company Overview
      • 6.2.4.2. Technology Snapshot
      • 6.2.4.3. Drug Portfolio
        • 6.2.4.3.1. Clinical Development
      • 6.2.4.4. Patents
      • 6.2.4.5. Collaborations
        • 6.2.4.5.1. Caliber Biotherapeutics
        • 6.2.4.5.2. Research Institutions
    • 6.2.5. miRagen Therapeutics
      • 6.2.5.1. Company Overview
      • 6.2.5.2. Financial Performance
      • 6.2.5.3. Drug Portfolio
        • 6.2.5.3.1. Preclinical Development
      • 6.2.5.4. Patents
      • 6.2.5.5. Collaborations
        • 6.2.5.5.1. Silence Therapeutics
        • 6.2.5.5.2. Servier
        • 6.2.5.5.3. Santaris Pharma A/S
        • 6.2.5.5.4. t2cure
        • 6.2.5.5.5. RXi Pharmaceuticals
        • 6.2.5.5.6. Archemix
        • 6.2.5.5.7. Research Collaborations
    • 6.2.6. Mirna Therapeutics
      • 6.2.6.1. Company Overview
      • 6.2.6.2. Financial Performance
      • 6.2.6.3. Technology Snapshot
      • 6.2.6.4. Drug Portfolio
        • 6.2.6.4.1. Clinical Development
        • 6.2.6.4.2. Preclinical Development
      • 6.2.6.5. Patents
      • 6.2.6.6. Collaborations
        • 6.2.6.6.1. Silence Therapeutics
        • 6.2.6.6.2. Marina Biotech
        • 6.2.6.6.3. RXi Pharmaceuticals
        • 6.2.6.6.4. Horizon Discovery
        • 6.2.6.6.5. Research Collaborations
    • 6.2.7. Quark Pharmaceuticals
      • 6.2.7.1. Company Overview
      • 6.2.7.2. Financial Performance
      • 6.2.7.3. Drug Portfolio
        • 6.2.7.3.1. Clinical Development
        • 6.2.7.3.2. Preclinical Development
      • 6.2.7.4. Patents
      • 6.2.7.5. Collaborations
        • 6.2.7.5.1. BioSpring
        • 6.2.7.5.2. Biocon
        • 6.2.7.5.3. Novartis
        • 6.2.7.5.4. Nitto Denko
        • 6.2.7.5.5. Silence Therapeutics
        • 6.2.7.5.6. Alnylam Pharmaceuticals
        • 6.2.7.5.7. Pfizer
        • 6.2.7.5.8. Other Companies
    • 6.2.8. RXi Pharmaceuticals
      • 6.2.8.1. Company Overview
      • 6.2.8.2. Financial Performance
      • 6.2.8.3. Technology Snapshot
      • 6.2.8.4. Drug Portfolio
        • 6.2.8.4.1. Clinical Development
        • 6.2.8.4.2. Preclinical Development
      • 6.2.8.5. Patents
      • 6.2.8.6. Collaborations
        • 6.2.8.6.1. MirImmune
        • 6.2.8.6.2. Ethicor
        • 6.2.8.6.3. OPKO
        • 6.2.8.6.4. EyeGate Pharma
        • 6.2.8.6.5. Mirna Therapeutics
        • 6.2.8.6.6. TransDerm
        • 6.2.8.6.7. miRagen Therapeutics
        • 6.2.8.6.8. Biogazelle
    • 6.2.9. Sirnaomics
      • 6.2.9.1. Company Overview
      • 6.2.9.2. Technology Snapshot
      • 6.2.9.3. Drug Portfolio
        • 6.2.9.3.1. Preclinical Development
      • 6.2.9.4. Patents
      • 6.2.9.5. Collaborations
        • 6.2.9.5.1. GuangshengZhongsheng
        • 6.2.9.5.2. Guangzhou Xiangxue
        • 6.2.9.5.3. General Research Laboratory (GRL)
  • 6.3. Europe
    • 6.3.1. Silence Therapeutics
      • 6.3.1.1. Company Overview
      • 6.3.1.2. Financial Performance
      • 6.3.1.3. Technology Snapshot
      • 6.3.1.4. Drug Portfolio
        • 6.3.1.4.1. Clinical Development
        • 6.3.1.4.2. Preclinical Development
      • 6.3.1.5. Patents
      • 6.3.1.6. Collaborations
        • 6.3.1.6.1. Quark Pharmaceuticals
        • 6.3.1.6.2. Astrazeneca
        • 6.3.1.6.3. Dainippon Sumitomo Pharma
        • 6.3.1.6.4. MiReven
        • 6.3.1.6.5. miRagen Therapeutics
        • 6.3.1.6.6. Mirna Therapeutics
        • 6.3.1.6.7. InteRNA Technologies
        • 6.3.1.6.8. Research Institutes
    • 6.3.2. Sylentis
      • 6.3.2.1. Company Overview
      • 6.3.2.2. Financial Performance
      • 6.3.2.3. Drug Portfolio
        • 6.3.2.3.1. Clinical Development
        • 6.3.2.3.2. Preclinical Development
      • 6.3.2.4. Patents
      • 6.3.2.5. Collaborations
        • 6.3.2.5.1. Alnylam Pharmaceuticals
        • 6.3.2.5.2. Nanopilot Project
        • 6.3.2.5.3. Project Teret
        • 6.3.2.5.4. Project Indreye
  • 6.4. Rest of the World
    • 6.4.1. Arbutus Biopharma (previously Tekmira)
      • 6.4.1.1. Company Overview
      • 6.4.1.2. Financial Performance
      • 6.4.1.3. Technology Snapshot
      • 6.4.1.4. Drug Portfolio
        • 6.4.1.4.1. Clinical Development
        • 6.4.1.4.2. Preclinical Development
      • 6.4.1.5. Patents
      • 6.4.1.6. Collaborations
        • 6.4.1.6.1. University of Oxford:
        • 6.4.1.6.2. Dicerna Pharmaceuticals
        • 6.4.1.6.3. Monsanto
        • 6.4.1.6.4. U.S Department of Defence (DoD)
        • 6.4.1.6.5. Merck
        • 6.4.1.6.6. Marina Biotech/Arcturus Therapeutics
        • 6.4.1.6.7. Alnylam Pharmaceuticals
        • 6.4.1.6.8. Halo-Bio RNAi Therapeutics
        • 6.4.1.6.9. BMS
    • 6.4.2. Benitec Biopharma
      • 6.4.2.1. Company Overview
      • 6.4.2.2. Financial Performance
      • 6.4.2.3. Technology Snapshot
      • 6.4.2.4. Drug Portfolio
        • 6.4.2.4.1. Clinical Development
        • 6.4.2.4.2. Preclinical Development
      • 6.4.2.5. Patents and Trademarks
      • 6.4.2.6. Collaborations
        • 6.4.2.6.1. Lonza
        • 6.4.2.6.2. Biomics Biopharma
        • 6.4.2.6.3. Royal Holloway University of London (RHUL) and the Institut de Myologie (IM) in Paris
        • 6.4.2.6.4. ReNeuron
        • 6.4.2.6.5. Omnia Biologics
        • 6.4.2.6.6. Asklepios
        • 6.4.2.6.7. CN Bio
        • 6.4.2.6.8. Circuit Therapeutics
        • 6.4.2.6.9. 4D Molecular Therapeutics
        • 6.4.2.6.10. Regen Biopharma
        • 6.4.2.6.11. Tacere Therapeutics
        • 6.4.2.6.12. uniQure
        • 6.4.2.6.13. Genable
        • 6.4.2.6.14. Calimmune
        • 6.4.2.6.15. Alnylam Pharmaceuticals
        • 6.4.2.6.16. CombiMatrix
        • 6.4.2.6.17. Revivicor
        • 6.4.2.6.18. MSD
        • 6.4.2.6.19. Avocel
        • 6.4.2.6.20. Other Collaborations
    • 6.4.3. Silenseed
      • 6.4.3.1. Company Overview
      • 6.4.3.2. Technology Snapshot
      • 6.4.3.3. Drug Portfolio
        • 6.4.3.3.1. Clinical Development
        • 6.4.3.3.2. Preclinical Development
      • 6.4.3.4. Patents

7. MARKET FORECAST

  • 7.1. Chapter Overview
  • 7.2. Scope and Limitations
  • 7.3. Forecast Methodology
  • 7.4. Overall RNAi Therapeutics Market, 2015-2030
  • 7.5. Individual Therapy Forecast
    • 7.5.1. Patisiran (ALN-TTR02) (Alnylam Pharmaceuticals)
      • 7.5.1.1. Target Population
      • 7.5.1.2. Sales Forecast
    • 7.5.2. Revusiran (ALN-TTRsc) (Alnylam Pharmaceuticals)
      • 7.5.2.1. Target Population
      • 7.5.2.2. Sales Forecast
    • 7.5.3. Vigil (Gradalis)
      • 7.5.3.1. Target Population
      • 7.5.3.2. Sales Forecast
    • 7.5.4. QPI-1007/ RQ-1007 (Quark Pharmaceuticals)
      • 7.5.4.1. Target Population
      • 7.5.4.2. Sales Forecast
    • 7.5.5. PF-655 (Quark Pharmaceuticals)
      • 7.5.5.1. Target Population
      • 7.5.5.2. Sales Forecast
    • 7.5.6. QPI-1002 (Quark Pharmaceuticals)
      • 7.5.6.1. Target Population
      • 7.5.6.2. Sales Forecast
    • 7.5.7. SYL040012 (Sylentis)
      • 7.5.7.1. Target Population
      • 7.5.7.2. Sales Forecast
    • 7.5.8. SYL1001 (Sylentis)
      • 7.5.8.1. Target Population
      • 7.5.8.2. Sales Forecast
    • 7.5.9. ARC-520 (Arrowhead Research)
      • 7.5.9.1. Target Population
      • 7.5.9.2. Sales Forecast
    • 7.5.10. SPC3649 (Roche Innovation Center Copenhagen (previously Santaris Pharma))
      • 7.5.10.1. Target Population
      • 7.5.10.2. Sales Forecast
    • 7.5.11. RXI-109 (RXi Pharmaceuticals)
      • 7.5.11.1. Target Population
      • 7.5.11.2. Sales Forecast

8. KEY THERAPEUTIC INDICATIONS

  • 8.1. Chapter Overview
  • 8.2. Infectious Diseases
    • 8.2.1. Hepatitis
      • 8.2.1.1. Hepatitis B
        • 8.2.1.1.1. Introduction and Epidemiology
        • 8.2.1.1.2. Market Landscape Overview
        • 8.2.1.1.3. RNAi and the Treatment of Hepatitis B
      • 8.2.1.2. Hepatitis C
        • 8.2.1.2.1. Introduction and Epidemiology
        • 8.2.1.2.2. Market Landscape Overview
        • 8.2.1.2.3. RNAi and the Treatment of Hepatitis C
  • 8.3. Oncology
    • 8.3.1. Solid Tumours
      • 8.3.1.1. Breast Cancer
        • 8.3.1.1.1. Introduction and Epidemiology
        • 8.3.1.1.2. Market Landscape Overview
        • 8.3.1.1.3. RNAi and the Treatment of Breast Cancer
      • 8.3.1.2. Colorectal Cancer
        • 8.3.1.2.1. Introduction and Epidemiology
        • 8.3.1.2.2. Market Landscape Overview
        • 8.3.1.2.3. RNAi and the Treatment of Colorectal Cancer
      • 8.3.1.3. Melanoma
        • 8.3.1.3.1. Introduction and Epidemiology
        • 8.3.1.3.2. Market Landscape Overview
        • 8.3.1.3.3. RNAi and the Treatment of Melanoma
      • 8.3.1.4. Non-Small Cell Lung Cancer
        • 8.3.1.4.1. Introduction and Epidemiology
        • 8.3.1.4.2. Market Landscape Overview
        • 8.3.1.4.3. RNAi and the Treatment of NSCLC
      • 8.3.1.5. Pancreatic Cancer
        • 8.3.1.5.1. Introduction and Epidemiology
        • 8.3.1.5.2. Market Landscape Overview
        • 8.3.1.5.3. RNAi and the Treatment of Pancreatic Cancer
    • 8.3.2. Haematological Malignancies
      • 8.3.2.1. Multiple Myeloma
        • 8.3.2.1.1. Introduction and Epidemiology
        • 8.3.2.1.2. Market Landscape Overview
        • 8.3.2.1.3. RNAi and the Treatment of Multiple Myeloma
      • 8.3.2.2. Non-Hodgkin Lymphoma (NHL)
        • 8.3.2.2.1. Introduction and Epidemiology
        • 8.3.2.2.2. Market Landscape Overview
        • 8.3.2.2.3. RNAi and the Treatment of NHL
  • 8.4. Ophthalmology
    • 8.4.1. Age-related Macular Degeneration (AMD)
      • 8.4.1.1. Introduction and Epidemiology
      • 8.4.1.2. Market Landscape Overview
      • 8.4.1.3. RNAi and the Treatment of AMD
  • 8.5. Cardiovascular Diseases
    • 8.5.1. Hypercholesterolemia
      • 8.5.1.1. Introduction and Epidemiology
      • 8.5.1.2. Market Landscape Overview
      • 8.5.1.3. RNAi and the Treatment of Hypercholesterolemia
    • 8.5.2. Hypertriglyceridemia (HTG)
      • 8.5.2.1. Introduction and Epidemiology
      • 8.5.2.2. Market Landscape Overview
      • 8.5.2.3. RNAi and the Treatment of Hypertriglyceridemia

9. RNAi AND DIAGNOSTICS

  • 9.1. Chapter Overview
  • 9.2. Characteristics of a Biomarker
  • 9.3. Circulating miRNAs as Biomarkers
  • 9.4. miRNA Biomarkers and Oncology
    • 9.4.1. Importance of Early Detection in Cancer
    • 9.4.2. Detecting Cancer: Screening vs. Diagnosis
    • 9.4.3. Conventional Invasive Cancer Diagnostic Tests
      • 9.4.3.1. Biopsy
    • 9.4.4. Need for Non-Invasive Approaches
    • 9.4.5. Key Oncological Indications
      • 9.4.5.1. Prostate Cancer
      • 9.4.5.2. Breast Cancer
      • 9.4.5.3. Lung Cancer
      • 9.4.5.4. Colorectal Cancer
      • 9.4.5.5. Gastric Cancer
      • 9.4.5.6. Haematological cancer
        • 9.4.5.6.1. Leukaemia
        • 9.4.5.6.2. Lymphoma
  • 9.5. miRNA Biomarkers and Cardiovascular Diseases
    • 9.5.1. Myocardial Infarction (MI)
    • 9.5.2. Coronary Artery Disease (CAD)
  • 9.6. Pipeline of miRNA Based Diagnostic Tests

10. VC FUNDING IN RNAI THERAPEUTICS

  • 10.1. Chapter Overview
  • 10.2. Instances of Funding in RNAi Therapeutics
  • 10.3. Rising Venture Capital Interest
  • 10.4. Distribution of the Funding Instances by Type of Funding
  • 10.5. Leading Players: Distribution by Number of Funding Instances

11. PARTNERSHIPS IN RNAi THERAPEUTICS

  • 11.1. Chapter Overview
  • 11.2. Partnership Models/Agreements
  • 11.3. Industrial Partnerships and Collaborations
  • 11.4. Collaborations with Research Institutes/Universities

12. SERVICE PROVIDERS IN RNAi THERAPEUTICS

  • 12.1. Chapter Overview
  • 12.2. Service Providers

13. SWOT ANALYSIS

  • 13.1. Overview
  • 13.2. Strengths
  • 13.3. Weakness
  • 13.4. Opportunities
  • 13.5. Threats

14. CONCLUSION

  • 14.1. RNAi Therapeutics: Targeting the Undruggable
  • 14.2. Active Collaborations Likely to be the Key to Future Success
  • 14.3. RNAi Therapeutics: An Emerging Market
  • 14.4. Delivery of RNAi Therapeutics: A Major Bottleneck
  • 14.5. A Strong Pipeline To Result in a Multi-Billion Dollar Market

15. APPENDIX 1: TABULATED DATA

16. APPENDIX 2: LIST OF COMPANIES AND ORGANISATIONS

List of Figures:

  • Figure 3.1: RNAi: Historical Evolution
  • Figure 3.2: Mechanism of RNAi
  • Figure 3.3: Types of Delivery Systems
  • Figure 3.4: Applications of RNAi
  • Figure 3.5: RNAi: Advantages and Disadvantages
  • Figure 4.1: RNAi Therapeutics: Distribution by Phase of Development
  • Figure 4.2: RNAi Clinical Pipeline: Distribution by Type of Molecule
  • Figure 4.3: RNAi Clinical Pipeline: Distribution by Type of Molecule and Phase of Clinical Development
  • Figure 4.4: RNAi Clinical Pipeline: Distribution by Therapeutic Area
  • Figure 4.5: RNAi Clinical Pipeline: Distribution by Route of Administration
  • Figure 4.6: RNAi Clinical Pipeline: Active Industry Players
  • Figure 4.7: RNAi Preclinical Pipeline: Distribution by Therapeutic Area
  • Figure 4.8: RNAi Preclinical Pipeline: Distribution by Type of Molecule
  • Figure 4.9: RNAi Preclinical Pipeline: Active Industry Players
  • Figure 5.1: Features of Lipoplex Technology Platform
  • Figure 5.2: Top Patent Filers: Total Patents Approved (US), 2013
  • Figure 5.3: Top Patent Filers: Break up by Type of Patent (US), 2013
  • Figure 5.4: Top Patent Filers: Pending Patent Applications (US), 2013
  • Figure 6.1: Alnylam Pharmaceuticals: Revenues, 2010-2015 (USD Million)
  • Figure 6.2: Alnylam Pharmaceuticals: Funding Instances (USD Million)
  • Figure 6.3: Alnylam Pharmaceuticals: Pipeline Overview
  • Figure 6.4: Arrowhead Research: Revenues, 2011-2015 (USD Thousands)
  • Figure 6.5: Arrowhead Research: Funding Instances (USD Million)
  • Figure 6.6: Arrowhead Research: Pipeline Overview
  • Figure 6.7: Dicerna Pharmaceuticals: Funding Instances (USD Million)
  • Figure 6.8: Dicerna Pharmaceuticals: Pipeline Overview
  • Figure 6.9: Gradalis: Pipeline Overview
  • Figure 6.10: miRagen Therapeutics: Funding Instances (USD Million)
  • Figure 6.11: miRagen Therapeutics: In-House Pipeline Overview
  • Figure 6.12: Mirna Therapeutics: Funding Instances (USD Million)
  • Figure 6.13: Mirna Therapeutics: Pipeline Overview
  • Figure 6.14: Quark Pharmaceuticals: Pipeline Overview
  • Figure 6.15: RXi Pharmaceuticals: Revenues, 2012-2015 (USD Thousands)
  • Figure 6.16: RXi Pharmaceuticals: Pipeline Overview
  • Figure 6.17: Sirnaomics: Pipeline Overview
  • Figure 6.18: Silence Therapeutics: Revenues, 2010-2014 (GBP Thousands)
  • Figure 6.19: Silence Therapeutics: Funding Instances (GBP Million)
  • Figure 6.20: Silence Therapeutics: Pipeline Overview
  • Figure 6.21: Sylentis: Funding Instances (EUR Million)
  • Figure 6.22: Sylentis: Pipeline Overview
  • Figure 6.23: Arbutus Biopharma: Revenues, 2010-2015 (USD Million)
  • Figure 6.24: Arbutus Biopharma: Funding Instances (USD Million)
  • Figure 6.25: Arbutus Biopharma: Pipeline Overview
  • Figure 6.26: Benitec Biopharma: Revenues, 2010-2014 (AUD Million)
  • Figure 6.27: Benitec Biopharma: Funding Instances (AUD Million)
  • Figure 6.28: Benitec Biopharma: Pipeline Overview
  • Figure 6.29: Silenseed: Pipeline Overview
  • Figure 7.1: Overall RNAi Therapeutics Market (USD Million), 2017-2030
  • Figure 7.2: Evolution of RNAi Therapeutics Market: 2020, 2025 &2030(Base Scenario)
  • Figure 7.3: Patisiran (ALN-TTR02) Sales Forecast, 2017-2030: Base Scenario (USD Million)
  • Figure 7.4: Revusiran (ALN-TTRsc) Sales Forecast, 2020-2030: Base Scenario (USD Million)
  • Figure 7.5: Vigil: Current Status by Highest Phase of Development
  • Figure 7.6: Vigil Sales Forecast, 2021-2030: Base Scenario (USD Million)
  • Figure 7.7: QPI-1007: Current Status by Highest Phase of Development
  • Figure 7.8: QPI-1007 Sales Forecast, 2020-2030: Base Scenario (USD Million)
  • Figure 7.9: PF-655: Current Status by Highest Phase of Development
  • Figure 7.10: PF-655 Sales Forecast, 2020-2030: Base Scenario (USD Million)
  • Figure 7.11: QPI-1002 Sales Forecast, 2020-2030: Base Scenario (USD Million)
  • Figure 7.12: SYL040012 Sales Forecast, 2021-2030: Base Scenario (USD Million)
  • Figure 7.13: SYL1001 Sales Forecast, 2021-2030: Base Scenario (USD Million)
  • Figure 7.14: ARC-520 Sales Forecast, 2021-2030: Base Scenario (USD Million)
  • Figure 7.15: SPC3649 Sales Forecast, 2021-2030: Base Scenario (USD Million)
  • Figure 7.16: RXI-109 Sales Forecast, 2021-2030: Base Scenario (USD Million)
  • Figure 8.1: Breast Cancer: Global Epidemiological Distribution
  • Figure 8.2: Colorectal Cancer: Global Epidemiological Distribution
  • Figure 8.3: Melanoma: Global Epidemiological Distribution
  • Figure 8.4: Lung Cancer: Global Epidemiological Distribution
  • Figure 8.5: Pancreatic Cancer: Global Epidemiological Distribution
  • Figure 8.6: Multiple Myeloma: Global Epidemiological Distribution
  • Figure 8.7: Lymphoma: Global Epidemiological Distribution
  • Figure 9.1: Factors Determining Useful Cancer Screening
  • Figure 9.2: Conventional Cancer Diagnosis Methods
  • Figure 9.3: Needle Biopsy and Open Biopsy: Demerits
  • Figure 10.1: Cumulative Funding Instances, Pre-2009-2015
  • Figure 10.2: Funding Instances: Total Amount Invested Annually (USD Million)
  • Figure 10.3: Funding Instances: Distribution by Type, Pre-2009-2015
  • Figure 10.4: Funding Instances: Distribution by Total Amount Invested, (USD Million)
  • Figure 10.5: Most Active Players: Distribution by Number of Funding Instances
  • Figure 10.6: Funding Instances: Distribution by Range of Amount Invested by Type of Funding (USD Million)
  • Figure 11.1: RNAi Therapeutics: Cumulative Partnership Instances, Pre-2005 - Mid-2015
  • Figure 11.2: Partnership Instances: Distribution by Types of Partnerships
  • Figure 11.3: RNAi Therapeutics: Leading Players by Partnerships
  • Figure 14.1: RNAi Therapeutics Market Forecast: Conservative, Base and Optimistic Scenarios, 2017-2030 (USD Million)

List of Tables:

  • Table 3.1: Merits and Demerits of Delivery Systems for RNAi
  • Table 3.2: Comparison Between siRNA, miRNA and shRNA
  • Table 4.1: RNAi Clinical Pipeline: Phase III
  • Table 4.2: RNAi Clinical Pipeline: Phase II and Phase I/II
  • Table 4.3: RNAi Clinical Pipeline: Phase I
  • Table 4.4: RNAi Clinical Pipeline: Research Institutes
  • Table 4.5: RNAi Preclinical Pipeline: Preclinical
  • Table 4.6: RNAi Preclinical Pipeline: Discovery
  • Table 5.1: Types of siRNA Triggers
  • Table 5.2: RNAi: Technology Platforms
  • Table 5.3: RNAi: Delivery Systems
  • Table 5.4: Delivery Systems Based on Lipoplex Technology
  • Table 5.5: Silence Therapeutics: Patent Portfolio
  • Table 5.6: Arbutus Biopharma: Patent Portfolio
  • Table 5.7: Dicerna Pharmaceuticals: Patent Portfolio
  • Table 5.8: Arrowhead Research: Patent Portfolio
  • Table 5.9: Alnylam Pharmaceuticals: Patent Portfolio
  • Table 5.10: Fundamental siRNA Patents
  • Table 6.1: Patisiran (ALN-TTR02): Clinical Trials
  • Table 6.2: Revusiran (ALN-TTRsc): Clinical Trials
  • Table 6.3: ALN-PCSsc: Clinical Trials
  • Table 6.4: ALN-RSV01: Clinical Trials
  • Table 6.5: ALN-AT3: Clinical Trials
  • Table 6.6: ALN-AAT: Clinical Trials
  • Table 6.7: ALN-CC5: Clinical Trials
  • Table 6.8: ALN-AS1: Clinical Trials
  • Table 6.9: ALN-VSP: Clinical Trials
  • Table 6.10: ARC-520: Clinical Trials
  • Table 6.11: ARC-AAT: Clinical Trials
  • Table 6.12: DCR-MYC: Clinical Trials
  • Table 6.13: Vigil: Clinical Trials
  • Table 6.14: Gradalis: Patent Portfolio
  • Table 6.15: miRagen Therapeutics: PatentPortfolio
  • Table 6.16: MRX34: Clinical Trials
  • Table 6.17: Mirna Therapeutics: Patent Portfolio
  • Table 6.18: QPI-1007: Clinical Trials
  • Table 6.19: PF-655: Clinical Trials
  • Table 6.20: QPI-1002 (I5NP): Clinical Trials
  • Table 6.21: Quark Pharmaceuticals: Patent Portfolio
  • Table 6.22: RXI-109: Clinical Trials
  • Table 6.23: RXi Pharmaceuticals: Patent Portfolio
  • Table 6.24: Sirnaomics: Patent Portfolio
  • Table 6.25: Atu027: Clinical Trials
  • Table 6.26: SYL040012: Clinical Trials
  • Table 6.27: SYL1001: Clinical Trials
  • Table 6.28: Sylentis: Patent Portfolio
  • Table 6.29: TKM-PLK1: Clinical Trials
  • Table 6.30: TKM-Ebola-Guinea: Clinical Trials
  • Table 6.31: TKM-Ebola-Kikwit: Clinical Trials
  • Table 6.32: TKM-HBV: Clinical Trials
  • Table 6.33: TT-034: Clinical Trials
  • Table 6.34: Benitec Biopharma: Patent Portfolio
  • Table 6.35: Benitec Biopharma: Trademark Portfolio
  • Table 6.36: siG12D LODER: Clinical Trials
  • Table 6.37: Silenseed: Patent Portfolio
  • Table 7.1: RNAi Therapeutics: Market Potential of Candidates
  • Table 8.1: Hepatitis B: Marketed Therapeutics
  • Table 8.2: Hepatitis B: RNAi Pipeline
  • Table 8.3: Hepatitis C: Marketed Therapeutics
  • Table 8.4: Hepatitis C: RNAi Pipeline
  • Table 8.5: Breast Cancer: Marketed Therapeutics
  • Table 8.6: Breast Cancer: RNAi Pipeline
  • Table 8.7: Colorectal Cancer: Marketed Targeted Therapeutics
  • Table 8.8: Colorectal Cancer: RNAi Pipeline
  • Table 8.9: Melanoma: Marketed Therapeutics
  • Table 8.10: Melanoma: RNAi Pipeline
  • Table 8.11: NSCLC: Marketed Therapeutics
  • Table 8.12: NSCLC: RNAi Pipeline
  • Table 8.13: Pancreatic Cancer: Marketed Therapeutics
  • Table 8.14: Pancreatic Cancer: RNAi Pipeline
  • Table 8.15: Multiple Myeloma: Marketed Therapeutics
  • Table 8.16: Multiple Myeloma: RNAi Pipeline
  • Table 8.17: Comparison of Hodgkin's and Non-Hodgkin's Lymphoma
  • Table 8.18: NHL: Marketed Therapeutics
  • Table 8.19: NHL: RNAi Pipeline
  • Table 8.20: Wet AMD: Marketed Therapeutics
  • Table 8.21: Wet AMD: RNAi Pipeline
  • Table 8.22: Hypercholesterolemia: Marketed Therapeutics
  • Table 8.23: Hypercholesterolemia: RNAi Pipeline
  • Table 8.24: Hypertriglyceridemia: Marketed Therapeutics
  • Table 8.25: Hypertriglyceridemia: RNAi Pipeline
  • Table 9.1: Ideal Biomarker v/s miRNA as a Biomarker
  • Table 9.2: Survival on Early Diagnosis of Cancer
  • Table 9.3: Cost of Biopsy for Different Cancer Indications (in USD)
  • Table 9.4: Prostate Cancer: Reported miRNA Biomarkers
  • Table 9.5: Breast Cancer: Reported miRNA Biomarkers
  • Table 9.6: Lung Cancer: Reported miRNA Biomarkers
  • Table 9.7: Colorectal Cancer: Reported miRNA Biomarkers
  • Table 9.8: Gastric Cancer: Reported miRNA Biomarkers
  • Table 9.9: AML: Reported miRNA Biomarkers
  • Table 9.10: de novo DLBCL: Reported miRNA Biomarkers
  • Table 9.11: MI: Reported miRNA Biomarkers
  • Table 9.12: CAD: Reported miRNA Biomarkers
  • Table 9.13: miRNA Diagnostic Tests: Pipeline
  • Table 10.1: List of Funding Instances in RNAi Therapeutics
  • Table 10.2: Types of Funding Instances, Pre-2009-2015
  • Table 11.1: RNAi Therapeutics: Industrial Partnerships
  • Table 11.2: RNAi Therapeutics: University Collaborations
  • Table 12.1: RNAi Therapeutics: Service Providers
  • Table 13.1: RNAi Therapeutics: SWOT Analysis
  • Table 13.2: Terminated siRNA Molecules
  • Table 15.1: RNAi Therapeutics: Distribution by Phase of Development
  • Table 15.2: RNAi Clinical Pipeline: Distribution by Type of Molecule
  • Table 15.3: RNAi Clinical Pipeline: Distribution by Type of Molecule & Phase of Clinical Development
  • Table 15.4: RNAi Clinical Pipeline: Distribution by Therapeutic Area
  • Table 15.5: RNAi Clinical Pipeline: Distribution by Route of Administration
  • Table 15.6: RNAi Clinical Pipeline: Active Players in the Industry
  • Table 15.7: RNAi Preclinical Pipeline: Distribution by Therapeutic Area
  • Table 15.8: RNAi Preclinical Pipeline: Distribution by Type of Molecule
  • Table 15.9: RNAi Preclinical Pipeline: Distribution by Therapeutic Area
  • Table 15.10: Top Patent Filters: Total Patents Approved (US), 2013
  • Table 15.11: Top Patent Filters: Break up by Type of Patent (US), 2013
  • Table 15.12: Top Patent Filters: Pending Patent Applications (US), 2013
  • Table 15.13: Alnylam Pharmaceuticals: Revenues, 2010-2015 (USD Million)
  • Table 15.14: Alnylam Pharmaceuticals: Funding Instances (USD Million)
  • Table 15.15: Arrowhead Research: Revenues, 2011-2015 (USD Thousands)
  • Table 15.16: Arrowhead Research: Funding Instances (USD Million)
  • Table 15.17: Dicerna Pharmaceuticals: Funding Instances (USD Million)
  • Table 15.18: miRagen Therapeutics: Funding Instances (USD Million)
  • Table 15.19: Mirna Therapeutics: Funding Instances (USD Million)
  • Table 15.20: RXi Pharmaceuticals: Revenues, 2012-2015 (USD Thousands)
  • Table 15.21: Silence Therapeutics: Revenues, 2010-2014 (GBP Thousands)
  • Table 15.22: Silence Therapeutics: Funding Instances (GBP Million)
  • Table 15.23: Sylentis: Funding Instances (EUR Million)
  • Table 15.24: Arbutus Biopharma: Revenues, 2010-2015 (USD Million)
  • Table 15.25: Arbutus Biopharma: Funding Instances (USD Million)
  • Table 15.26: Benitec Biopharma: Revenues, 2010-2014 (AUD Million)
  • Table 15.27: Benitec Biopharma: Funding Instances (AUD Million)
  • Table 15.28: Overall RNAi Therapeutics Market, 2017-2030: Conservative Scenario, Base Scenario & Optimistic Scenario (USD Million)
  • Table 15.29: ALN-TTR02: Sales Forecast, 2017-2030: Conservative Scenario, Base Scenario & Optimistic Scenario (USD Million)
  • Table 15.30: ALN-TTRsc: Sales Forecast, 2020-2030: Conservative Scenario, Base Scenario & Optimistic Scenario (USD Million)
  • Table 15.31: Vigil: Sales Forecast, 2021-2030: Conservative Scenario, Base Scenario & Optimistic Scenario (USD Million)
  • Table 15.32: QPI-1007: Sales Forecast, 2020-2030: Conservative Scenario, Base Scenario & Optimistic Scenario (USD Million)
  • Table 15.33: PF-655: Sales Forecast, 2020-2030: Conservative Scenario, Base Scenario & Optimistic Scenario (USD Million)
  • Table 15.34: QPI-1002: Sales Forecast, 2020-2030: Conservative Scenario, Base Scenario & Optimistic Scenario (USD Million)
  • Table 15.35: SYL040012: Sales Forecast, 2020-2030: Conservative Scenario, Base Scenario & Optimistic Scenario (USD Million)
  • Table 15.36: SYL1001: Sales Forecast, 2021-2030: Conservative Scenario, Base Scenario & Optimistic Scenario (USD Million)
  • Table 15.37: ARC-520: Sales Forecast, 2021-2030: Conservative Scenario, Base Scenario & Optimistic Scenario (USD Million)
  • Table 15.38: SPC3649: Sales Forecast, 2021-2030: Conservative Scenario, Base Scenario & Optimistic Scenario (USD Million)
  • Table 15.39: RXI-109: Sales Forecast, 2021-2030: Conservative Scenario, Base Scenario & Optimistic Scenario (USD Million)
  • Table 15.40: Cumulative Funding Instances, Pre-2009-2015
  • Table 15.41: Funding Instances: Total Amount Invested Annually (USD Million)
  • Table 15.42: Most Active Players: Distribution by Number of Funding Instances
  • Table 15.43: RNAi Therapeutics: Cumulative Partnership Instances, Pre-2005 - Mid-2015
  • Table 15.44: Partnership Instances: Distribution by Types of Partnerships
  • Table 15.45: RNAi Therapeutics: Leading Players by Partnership
  • Table 15.46: RNAi Therapeutics Market Forecast: Conservative, Base and Optimistic Scenarios, 2017, 2024 and 2030(USD Million)

Listed Companies

The following companies have been mentioned in this report.

  • 1. 4D Molecular Therapeutics
  • 2. AbbVie
  • 3. Abion
  • 4. Abott Labs
  • 5. Advirna
  • 6. Aegerion Pharmaceuticals
  • 7. Aligent Technologies
  • 8. Allele Biotechnology
  • 9. Altogen Labs
  • 10. Alnylam Pharmaceuticals
  • 11. Amarin
  • 12. Ambion
  • 13. Amgen
  • 14. amsbio
  • 15. AparnaBio
  • 16. Arbutus Biopharma (previously Tekmira)
  • 17. Archemix
  • 18. Arcturus Therapeutics
  • 19. Ariz Biopharma
  • 20. Arrowhead Research Corporation
  • 21. Artemis
  • 22. Ascletis Pharmaceuticals
  • 23. Asklepios
  • 24. Astellas Pharma
  • 25. AstraZeneca
  • 26. Asuragen
  • 27. Avidity NanoMedicines
  • 28. Avocel
  • 29. Bayer Heathcare
  • 30. Benitec Biopharma
  • 31. biOasis Technologies
  • 32. Biocon
  • 33. BioDefense Therapeutics
  • 34. Biogazelle
  • 35. Biogen
  • 36. Biomics
  • 37. Bioneer
  • 38. BioSpring
  • 39. Bristol-Myers Sqibb
  • 40. Boehringer Ingelheim
  • 41. Calando Pharmaceuticals
  • 42. Caliber Biotherapeutics
  • 43. Calimmune
  • 44. Celgene
  • 45. Cell Signaling Technology
  • 46. Cellecta
  • 47. Celsion Corporation
  • 48. Cenix Biosciences
  • 49. Cepheid
  • 50. Circuit Therapeutics
  • 51. CN Bio
  • 52. CombiMatrix
  • 53. Creative Animodel
  • 54. Cubist
  • 55. Dainppon Sumitomo Pharma
  • 56. Dharmacon (GE unit)
  • 57. DIAMIR
  • 58. Dicerna Pharmaceuticals
  • 59. Eisai
  • 60. Eli Lilly
  • 61. enGene
  • 62. Ensysce Biosciences
  • 63. Ethicor
  • 64. Eurofins Genomics
  • 65. Eurogentec
  • 66. Exiqon
  • 67. EyeGate Pharma
  • 68. Eyetech
  • 69. Genable
  • 70. Genecare Research Institute
  • 71. Genecon Biotech
  • 72. GeneCopoeia
  • 73. Genecust
  • 74. GeneDesign
  • 75. Genentech
  • 76. GenePharma
  • 77. General Research Laboratory
  • 78. GenScript
  • 79. Gensignia
  • 80. Genzyme
  • 81. Gilead Sciences
  • 82. Gradalis
  • 83. Groove Biopharma
  • 84. GlaxoSmithKline
  • 85. GuangshengZhongsheng
  • 86. Guangzhou Xiangxue
  • 87. Halo-bio
  • 88. Horizon Discovery
  • 89. Hugel
  • 90. Interna Technologies
  • 91. Intezyne
  • 92. Ipsen
  • 93. Isis Pharmaceuticals
  • 94. Janssen Pharma
  • 95. Kowa Pharmaceuticals
  • 96. Kyowa Hakko Kirin
  • 97. Life Technologies
  • 98. Lonza
  • 99. MD Anderson Cancer Center
  • 100. Marina Biotech
  • 101. Medtronic
  • 102. Mello Biotech
  • 103. Microlin Bio
  • 104. Millennium Pharmaceuticals
  • 105. miRagen Therapeutics
  • 106. MiReven
  • 107. MirImmune
  • 108. Mirna Therapeutics
  • 109. Mitsubishi Pharma Corporation
  • 110. Monsanto
  • 111. Merck & Co (US)
  • 112. Nitto Denko Corporation
  • 113. Novartis
  • 114. Olix Pharmaceuticals
  • 115. Omnia Biologics
  • 116. Onco Therapy Science
  • 117. OPKO
  • 118. OriGene
  • 119. PeptiMed
  • 120. Pfizer
  • 121. PhaseRx
  • 122. Promega
  • 123. Qiagen
  • 124. QLT Phototherapeutics
  • 125. Quark Pharmaceuticals
  • 126. Regen BioPharma
  • 127. Regulus Therapeutics
  • 128. ReNeuron
  • 129. Revivicor
  • 130. Rhone Poulenc Rorer
  • 131. Rosetta Genomics
  • 132. RXi Therapeutics
  • 133. Sankyo Co.
  • 134. Sanofi-Aventis
  • 135. Santaris Pharma/Roche
  • 136. Sanwa Kagaku Kenkyusho
  • 137. Schering
  • 138. Seattle Genetics
  • 139. Servier
  • 140. Sevion Therapeutics
  • 141. Shanghai Biotechnology Corporation
  • 142. Shionogi & Co.
  • 143. Sigma-Aldrich
  • 144. Silence Therapeutics
  • 145. Silenseed
  • 146. Sirion Biotech
  • 147. Sirnaomics
  • 148. siRNAsense
  • 149. siTools Biotech
  • 150. Soluventis
  • 151. Somagenics
  • 152. Spectrum Pharmaceuticals
  • 153. Sylentis
  • 154. t2cure
  • 155. Taisho Pharmaceuticals
  • 156. Takeda Pharmaceutical Co.
  • 157. The Medicines Company
  • 158. TransDerm
  • 159. Transgene Biotek
  • 160. TransOMIC
  • 161. UniQure
  • 162. YuYu Pharma
Back to Top